STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models.
Ontology highlight
ABSTRACT: Pancreatic cancer is characterized by an immune suppressive stromal reaction that creates a barrier to therapy. A murine transgenic pancreatic cancer cell line that recapitulates human disease was used to test whether a STimulator of Interferon Genes (STING) agonist could reignite immunologically inert pancreatic tumors. STING agonist treatment potently changed the tumor architecture, altered the immune profile, and increased the survival of tumor-bearing mice. Notably, STING agonist increased numbers and activity of cytotoxic T cells within tumors and decreased levels of suppressive regulatory T cells. Further, STING agonist treatment upregulated costimulatory molecule expression on cross-presenting dendritic cells and reprogrammed immune-suppressive macrophages into immune-activating sub
SUBMITTER: Jing W
PROVIDER: S-EPMC6489306 | biostudies-literature | 2019 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA